Immune Checkpoint Status and Exhaustion-related Phenotypes of CD8 T Cells from the Tumor-draining Regional Lymph Nodes in Breast Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 Dec 9

PMID 38069525

Authors

Izel Yilmaz

Ece Tavukcuoglu

Utku Horzum

Kerim Bora Yilmaz

Melih Akinci

Mehmet Ali Gulcelik

Haluk Barbaros Oral

Gunes Esendagli

Affiliations

Soon will be listed here.

Abstract

Background: Functional status of T cells determines the responsiveness of cancer patients to immunotherapeutic interventions. Even though T cell-mediated immunity is inaugurated in the tumor-adjacent lymph nodes, peripheral blood has been routinely sampled for testing the immunological assays. The purpose of this study is to determine the immune checkpoint molecule expression and the exhaustion-related phenotype of cytotoxic T cells in the regional lymph nodes from breast cancer patients.

Patients And Methods: Multicolor immunophenotyping was used to determine the expression of PD-1, TIM-3, LAG3, CTLA-4, CCR7, CD45RO, CD127, CD25, CXCR5, and ICOS molecules on CD3 CD4 CD56 CD8 cytotoxic T cells freshly obtained from the lymph nodes and the peripheral blood samples of the breast cancer patients. The results were assessed together with the clinical data.

Results: A population of cytotoxic T cells was noted with high PD-1 and CXCR5 expression in the lymph nodes of the breast cancer patients. Co-expression of PD-1, CXCR5, TIM-3, and ICOS indicated a follicular helper T cell (Tfh)-like, exhaustion-related immunophenotype in these cytotoxic T cells. Only a minor population with CTLA-4 and LAG3 expression was noted. The PD-1 CXCR5 cytotoxic T cells largely displayed CD45RO CCR7 central memory markers. The amount of CXCR5-expressing PD-1 cytotoxic T cells was elevated in the lymph nodes of the patients.

Conclusion: The regional lymph nodes of breast cancer patients harbor Tfh-like exhausted cytotoxic T lymphocytes with high PD-1 and TIM-3 checkpoint molecule expression. The immunological conditions in the regional lymph nodes should be implicated for immune checkpoint immunotherapy (ICI) of cancer.

Citing Articles

MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy.

Deshpande R, Wu K, Wu S, Tyagi A, Smith E, Kim J EMBO Mol Med. 2025; .

PMID: 40087501 DOI: 10.1038/s44321-025-00213-7.

New Emerging Chemokine Receptors: CCR5 or CXCR5 on Tumor Is Associated with Poor Response to Chemotherapy and Poor Prognosis in Locally Advanced Triple-Negative Breast Cancer.

Cabioglu N, Onder S, Karatay H, Bayram A, Oner G, Tukenmez M Cancers (Basel). 2024; 16(13).

PMID: 39001456 PMC: 11240792. DOI: 10.3390/cancers16132388.

Immune checkpoint status and exhaustion-related phenotypes of CD8 T cells from the tumor-draining regional lymph nodes in breast cancer.

Yilmaz I, Tavukcuoglu E, Horzum U, Yilmaz K, Akinci M, Gulcelik M Cancer Med. 2023; 12(24):22196-22205.

PMID: 38069525 PMC: 10757146. DOI: 10.1002/cam4.6802.

References

Horn S, Borrero-Wolff D, Ritter M, Arndts K, Wiszniewsky A, Debrah L . Distinct Immune Profiles of Exhausted Effector and Memory CD8 T Cells in Individuals With Filarial Lymphedema. Front Cell Infect Microbiol. 2021; 11:680832. PMC: 8415778. DOI: 10.3389/fcimb.2021.680832. View

Blackburn S, Shin H, Freeman G, Wherry E . Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A. 2008; 105(39):15016-21. PMC: 2567485. DOI: 10.1073/pnas.0801497105. View

Chen Z, Ji Z, Ngiow S, Manne S, Cai Z, Huang A . TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. Immunity. 2019; 51(5):840-855.e5. PMC: 6943829. DOI: 10.1016/j.immuni.2019.09.013. View

Havenar-Daughton C, Lindqvist M, Heit A, Wu J, Reiss S, Kendric K . CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci U S A. 2016; 113(10):2702-7. PMC: 4790995. DOI: 10.1073/pnas.1520112113. View

Wang Y, Dong T, Xuan Q, Zhao H, Qin L, Zhang Q . Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer. J Breast Cancer. 2018; 21(2):124-133. PMC: 6015973. DOI: 10.4048/jbc.2018.21.2.124. View

Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher I, Sander C . Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010; 207(10):2175-86. PMC: 2947081. DOI: 10.1084/jem.20100637. View

Chen Y, Yu M, Zheng Y, Fu G, Xin G, Zhu W . CXCR5PD-1 follicular helper CD8 T cells control B cell tolerance. Nat Commun. 2019; 10(1):4415. PMC: 6765049. DOI: 10.1038/s41467-019-12446-5. View

Im S, Hashimoto M, Gerner M, Lee J, Kissick H, Burger M . Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016; 537(7620):417-421. PMC: 5297183. DOI: 10.1038/nature19330. View

Zhu S, Lin J, Qiao G, Wang X, Xu Y . Tim-3 identifies exhausted follicular helper T cells in breast cancer patients. Immunobiology. 2016; 221(9):986-93. DOI: 10.1016/j.imbio.2016.04.005. View

10.

Sakuishi K, Apetoh L, Sullivan J, Blazar B, Kuchroo V, Anderson A . Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010; 207(10):2187-94. PMC: 2947065. DOI: 10.1084/jem.20100643. View

11.

Garcia-Aranda M, Redondo M . Immunotherapy: A Challenge of Breast Cancer Treatment. Cancers (Basel). 2019; 11(12). PMC: 6966503. DOI: 10.3390/cancers11121822. View

12.

Bai M, Zheng Y, Liu H, Su B, Zhan Y, He H . CXCR5 CD8 T cells potently infiltrate pancreatic tumors and present high functionality. Exp Cell Res. 2017; 361(1):39-45. DOI: 10.1016/j.yexcr.2017.09.039. View

13.

Yang H, Sun B, Ma W, Fan L, Xu K, Jia Y . Multi-scale characterization of tumor-draining lymph nodes in resectable lung cancer treated with neoadjuvant immune checkpoint inhibitors. EBioMedicine. 2022; 84:104265. PMC: 9486045. DOI: 10.1016/j.ebiom.2022.104265. View

14.

Miller B, Sen D, Al Abosy R, Bi K, Virkud Y, LaFleur M . Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019; 20(3):326-336. PMC: 6673650. DOI: 10.1038/s41590-019-0312-6. View

15.

Wall I, Boulat V, Shah A, Blenman K, Wu Y, Alberts E . Leveraging the Dynamic Immune Environment Triad in Patients with Breast Cancer: Tumour, Lymph Node, and Peripheral Blood. Cancers (Basel). 2022; 14(18). PMC: 9496983. DOI: 10.3390/cancers14184505. View

16.

Xing J, Zhang C, Yang X, Wang S, Wang Z, Li X . CXCR5CD8 T cells infiltrate the colorectal tumors and nearby lymph nodes, and are associated with enhanced IgG response in B cells. Exp Cell Res. 2017; 356(1):57-63. DOI: 10.1016/j.yexcr.2017.04.014. View

17.

Cance W, Carey L, Calvo B, Sartor C, Sawyer L, Moore D . Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg. 2002; 236(3):295-302; discussion 302-3. PMC: 1422583. DOI: 10.1097/01.SLA.0000027526.67560.64. View

18.

Tang J, Zha J, Guo X, Shi P, Xu B . CXCR5CD8 T cells present elevated capacity in mediating cytotoxicity toward autologous tumor cells through interleukin 10 in diffuse large B-cell lymphoma. Int Immunopharmacol. 2017; 50:146-151. DOI: 10.1016/j.intimp.2017.06.020. View

19.

Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco S, Calderon-Copete S, Pais Ferreira D . Intratumoral Tcf1PD-1CD8 T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity. 2019; 50(1):195-211.e10. DOI: 10.1016/j.immuni.2018.12.021. View

20.

Dong C, Juedes A, Temann U, Shresta S, Allison J, Ruddle N . ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 2001; 409(6816):97-101. DOI: 10.1038/35051100. View